Corey A Siegel

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3468318/publications.pdf

Version: 2024-02-01

138 papers	6,516 citations	61857 43 h-index	71532 76 g-index
199 all docs	199 docs citations	199 times ranked	5869 citing authors

#	Article	IF	Citations
1	ACG Clinical Guideline: Ulcerative Colitis in Adults. American Journal of Gastroenterology, 2019, 114, 384-413.	0.2	933
2	Risk of Lymphoma Associated With Combination Antiâ€“Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis. Clinical Gastroenterology and Hepatology, 2009, 7, 874-881.	2.4	459
3	The Real-World Effectiveness and Safety of Vedolizumab for Moderateâ€“Severe Crohnâ€™s Disease: Results From the US VICTORY Consortium. American Journal of Gastroenterology, 2016, 111, 1147-1155.	0.2	257
4	Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis. Gastroenterology, 2015, 148, 344-354.e5.	0.6	226
5	Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2019, 17, 1655-1668.e3.	2.4	214
6	Management of Patients With Crohnâ€™s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. Gastroenterology, 2020, 159, 6-13.e6.	0.6	185
7	SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut, 2021, 70, 635-640.	6.1	173
8	Crohnâ€™s Disease Patientsâ€™ Risk-Benefit Preferences: Serious Adverse Event Risks Versus Treatment Efficacy. Gastroenterology, 2007, 133, 769-779.	0.6	167
9	Risks of Serious Infection or Lymphoma With Antiâ€“Tumor NecrosisÂFactor Therapy for Pediatric Inflammatory Bowel Disease: AÂSystematic Review. Clinical Gastroenterology and Hepatology, 2014, 12, 1443-1451.	2.4	137
10	Risks and Benefits of Infliximab for the Treatment of Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 1017-1024.	2.4	130
11	Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. American Journal of Gastroenterology, 2018, 113, 1345.	0.2	119
12	Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Antiâ€“Tumor Necrosis Factor Therapy for Crohnâ€™s Disease: A Meta-analysis of Placebo-controlled Trials. Clinical Gastroenterology and Hepatology, 2015, 13, 2233-2240.e2.	2.4	109
13	Development of an index to define overall disease severity in IBD. Gut, 2018, 67, 244-254.	6.1	108
14	Systematic review: monotherapy with antitumour necrosis factor Î± agents versus combination therapy with an immunosuppressive for IBD. Gut, 2014, 63, 1843-1853.	6.1	106
15	Developing a Standard Set of Patient-Centred Outcomes for Inflammatory Bowel Diseaseâ€”an International, Cross-disciplinary Consensus. Journal of Crohn's and Colitis, 2018, 12, 408-418.	0.6	102
16	Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohnâ€™sÂDisease. Gastroenterology, 2018, 155, 687-695.e10.	0.6	93
17	A Comprehensive Literature Review and Expert Consensus Statement on Therapeutic Drug Monitoring of Biologics in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2021, 116, 2014-2025.	0.2	93
18	Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. Gut, 2012, 61, 459-465.	6.1	91

#	Article	IF	Citations
19	Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD. Inflammatory Bowel Diseases, 2017, 23, 570-577.	0.9	78
20	Real-time tool to display the predicted disease course and treatment response for children with CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2011, 17, 30-38.	0.9	72
21	The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organisation: Safety. American Journal of Gastroenterology, 2011, 106, 1594-1602.	0.2	71
22	Review: Predicting response to anti-TNF agents for the treatment of Crohn's disease. Therapeutic Advances in Gastroenterology, 2009, 2, 245-251.	1.4	69
23	Patient Preferences for Surgical Versus Medical Therapy for Ulcerative Colitis. Inflammatory Bowel Diseases, 2014, 20, 103-114.	0.9	67
24	Challenges in IBD Research: Precision Medicine. Inflammatory Bowel Diseases, 2019, 25, S31-S39.	0.9	67
25	Patient perceptions of the risks and benefits of infliximab for the treatment of inflammatory bowel disease. Inflammatory Bowel Diseases, 2008, 14, 1-6.	0.9	61
26	Are Gastroenterologists Less Tolerant of Treatment Risks than Patients? Benefit-Risk Preferences in Crohn's Disease Management. Journal of Managed Care Pharmacy, 2010, 16, 616-628.	2.2	61
27	Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2019, 17, 1533-1540.e2.	2.4	60
28	The Impact of Ulcerative Colitis on Patientsâ€™ Lives Compared to Other Chronic Diseases: A Patient Survey. Digestive Diseases and Sciences, 2010, 55, 1044-1052.	1.1	57
29	Transforming Gastroenterology Care With Telemedicine. Gastroenterology, 2017, 152, 958-963.	0.6	57
30	Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative Colitis. Gastroenterology, 2018, 155, 1008-1011.e8.	0.6	56
31	When should ulcerative colitis patients undergo colectomy for dysplasia? Mismatch between patient preferences and physician recommendations. Inflammatory Bowel Diseases, 2010, 16, 1658-1662.	0.9	51
32	Do Inflammatory Bowel Disease Therapies Cause Cancer?. Inflammatory Bowel Diseases, 2013, 19, 1306-1321.	0.9	51
33	Lymphoma risk in children and young adults with inflammatory bowel disease: Analysis of a large single-center cohort. Inflammatory Bowel Diseases, 2012, 18, 838-843.	0.9	50
34	Delivering High Value Inflammatory Bowel Disease Care Through Telemedicine Visits. Inflammatory Bowel Diseases, 2017, 23, 1678-1681.	0.9	50
35	Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 2461-2467.	0.9	50
36	Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 669-681.	1.9	48

#	Article	IF	Citations
37	Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2020, 18, 2952-2961.e8.	2.4	48
38	Medical Marijuana for Digestive Disorders: High Time to Prescribe?. American Journal of Gastroenterology, 2015, 110, 208-214.	0.2	47
39	Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized, double-blind, sham-controlled trial. American Journal of Gastroenterology, 2018, 113, 1516-1523.	0.2	47
40	Risk factors for colorectal cancer in CrohnÊ¼s colitis: A case-control study. Inflammatory Bowel Diseases, 2006, 12, 491-496.	0.9	46
41	The Appropriateness of Concomitant Immunomodulators With Antiâ€“Tumor Necrosis Factor Agents for Crohn's Disease: One Size Does Not Fit All. Clinical Gastroenterology and Hepatology, 2010, 8, 655-659.	2.4	46
42	Adverse Events Do Not Outweigh Benefits of Combination Therapy for Crohn's Disease in a Decision Analytic Model. Clinical Gastroenterology and Hepatology, 2012, 10, 46-51.	2.4	45
43	Translating Improved Quality of Care Into an Improved Quality of Life for Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2013, 11, 908-912.	2.4	45
44	Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2020, 18, 2526-2534.e9.	2.4	45
45	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clinical Gastroenterology and Hepatology, 2018, 16, 637-647.e13.	2.4	44
46	Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohnâ€™s Disease But Not Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2497-2505.e1.	2.4	44
47	Heterogeneity in Definitions of Efficacy and Safety EndpointsÂforÂClinical Trials of Crohnâ€™s Disease: AÂSystematicÂReview. Clinical Gastroenterology and Hepatology, 2018, 16, 1407-1419.e22.	2.4	41
48	The Risk of Malignancy Associated with the Use of Biological Agents in Patients with Inflammatory Bowel Disease. Gastroenterology Clinics of North America, 2014, 43, 525-541.	1.0	39
49	Are Adult Patients More Tolerant of Treatment Risks Than Parents of Juvenile Patients?. Risk Analysis, 2009, 29, 121-136.	1.5	38
50	Appropriateness of Testing for Antiâ€“Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation ofÂResults. Clinical Gastroenterology and Hepatology, 2016, 14, 1302-1309.	2.4	36
51	Inflammatory bowel disease-patients are insufficiently educated about the basic characteristics of their disease and the associated risk of colorectal cancer. Digestive and Liver Disease, 2010, 42, 777-784.	0.4	35
52	Fostering Collaboration Through Creation of an IBD Learning Health System. American Journal of Gastroenterology, 2017, 112, 406-408.	0.2	35
53	Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States. Clinical and Translational Gastroenterology, 2020, 11, e00128.	1.3	35
54	Gastroenterologistsâ€™ Views of Shared Decision Making for Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2015, 60, 2636-2645.	1.1	34

#	Article	IF	Citations
55	Systematic review: hepatosplenic Tâ€cell lymphoma on biologic therapy for inflammatory bowel disease, including data from the Food and Drug Administration Adverse Event Reporting System. Alimentary Pharmacology and Therapeutics, 2020, 51, 527-533.	1.9	34
56	A Survey Study of Gastroenterologistsâ€™ Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 191-197.	0.9	33
57	Novel Statistical Approach to Determine Inflammatory Bowel Disease: Patientsâ€™ Perspectives on Shared Decision Making. Patient, 2016, 9, 79-89.	1.1	32
58	Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2022, 20, 126-135.	2.4	32
59	Prospective Cohort Study to Investigate the Safety of Preoperative Tumor Necrosis Factor Inhibitor Exposure in Patients With Inflammatory Bowel Disease Undergoing Intra-abdominal Surgery. Gastroenterology, 2022, 163, 204-221.	0.6	32
60	Challenges in IBD Research. Inflammatory Bowel Diseases, 2013, 19, 677-682.	0.9	31
61	Patients with Ulcerative Colitis Are More Concerned About Complications of Their Disease than Side Effects of Medications. Inflammatory Bowel Diseases, 2016, 22, 940-947.	0.9	29
62	Patientâ€™s Perspectives Important for Early Anti-Tumor Necrosis Factor Treatment in Inflammatory Bowel Disease. Digestion, 2009, 79, 30-35.	1.2	28
63	Decreased Antibody Responses to Ad26.COV2.S Relative to SARS-CoV-2 mRNA Vaccines in Patients With Inflammatory Bowel Disease. Gastroenterology, 2021, 161, 2041-2043.e1.	0.6	27
64	Making therapeutic decisions in inflammatory bowel disease: the role of patients. Current Opinion in Gastroenterology, 2009, 25, 334-338.	1.0	26
65	Balancing and Communicating the Risks and Benefits of Biologics in Pediatric Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 2927-2936.	0.9	25
66	Lost in translation. Inflammatory Bowel Diseases, 2010, 16, 2168-2172.	0.9	24
67	A Phase 2, Randomized, Placebo-Controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients With Moderately to Severely Active Crohnâ€™s Disease. Journal of Crohn's and Colitis, 2018, 12, 1014-1020.	0.6	24
68	The Inflammatory Bowel Disease Live Interinstitutional and Interdisciplinary Videoconference Education (IBD LIVE) Series. Inflammatory Bowel Diseases, 2014, 20, 1687-1695.	0.9	23
69	Colorectal cancer in Crohnâ€™s colitis is comparable to sporadic colorectal cancer. International Journal of Colorectal Disease, 2016, 31, 973-982.	1.0	23
70	Defining Failure of Medical Therapy for Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 74-77.	0.9	22
71	Identifying Patients With Inflammatory Bowel Diseases atÂHigh vs Low Risk of Complications. Clinical Gastroenterology and Hepatology, 2020, 18, 1261-1267.	2.4	22
72	Increasing Patient Activation Could Improve Outcomes for Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 2975-2978.	0.9	21

#	Article	IF	Citations
73	Antiâ€“Tumor Necrosis Factor-Î± Monotherapy Versus Combination Therapy with an Immunomodulator in IBD. Gastroenterology Clinics of North America, 2014, 43, 441-456.	1.0	20
74	Using Proactive Therapeutic Drug Monitoring of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: From an Old Concept to a Future Standard of Care?. Gastroenterology, 2018, 154, 1201-1202.	0.6	20
75	A Web-based Multimedia Program Before Colonoscopy Increased Knowledge and Decreased Anxiety, Sedation Requirement, and Procedure Time. Journal of Clinical Gastroenterology, 2018, 52, 519-523.	1.1	19
76	Quality Improvement Initiatives in Inflammatory Bowel Disease. Current Gastroenterology Reports, 2017, 19, 41.	1.1	18
77	Refocusing IBD Patient Management: Personalized, Proactive, and Patient-Centered Care. American Journal of Gastroenterology, 2018, 113, 1440-1443.	0.2	18
78	Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2021, 27, 1443-1451.	0.9	18
79	Embracing the internet for progress in shared decision-making. Inflammatory Bowel Diseases, 2007, 13, 1579-1580.	0.9	17
80	Perspectives From Patients and Gastroenterologists on De-escalating Therapy for Crohnâ€™s Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 403-405.	2.4	17
81	Proactive infliximab optimisation using a pharmacokinetic dashboard versus standard of care in patients with Crohnâ€™s disease: study protocol for a randomised, controlled, multicentre, open-label study (the OPTIMIZE trial). BMJ Open, 2022, 12, e057656.	0.8	17
82	Prognosticating the Course of Inflammatory Bowel Disease. Gastrointestinal Endoscopy Clinics of North America, 2019, 29, 395-404.	0.6	15
83	A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares. Alimentary Pharmacology and Therapeutics, 2020, 52, 955-963.	1.9	15
84	Development and Pilot Testing of the Inflammatory Bowel Disease Nutrition Care Pathway. Clinical Gastroenterology and Hepatology, 2020, 18, 2645-2649.e4.	2.4	15
85	Comparison of Assays for Therapeutic Monitoring of Infliximab and Adalimumab in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2021, 19, 839-841.e2.	2.4	15
86	Systems-Based Strategies to Consider Treatment Costs in Clinical Practice. Clinical Gastroenterology and Hepatology, 2020, 18, 1010-1014.	2.4	14
87	Infliximab and Adalimumab Concentrations May Vary Between the Enzyme-Linked Immunosorbent Assay and the Homogeneous Mobility Shift Assay in Patients With Inflammatory Bowel Disease: A Prospective Cross-Sectional Observational Study. Inflammatory Bowel Diseases, 2019, 25, e143-e145.	0.9	13
88	Predictors of Clinical and Endoscopic Response with Vedolizumab for the Treatment of Moderately-Severely Active Ulcerative Colitis: Results from the us Victory Consortium. Gastroenterology, 2017, 152, S371.	0.6	12
89	Quality of Care Program Reduces Unplanned Health Care Utilization in Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2021, 116, 2410-2418.	0.2	12
90	Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. Inflammatory Bowel Diseases, 2019, 25, 1854-1861.	0.9	11

#	Article	IF	Citations
91	A pilot feasibility trial of cognitiveâ€“behavioural therapy for insomnia in people with inflammatory bowel disease. BMJ Open Gastroenterology, 2021, 8, e000805.	1.1	11
92	Patientsâ€™ Perceive Biologics to Be Riskier and More Dreadful Than Other IBD Medications. Inflammatory Bowel Diseases, 2020, 26, 141-146.	0.9	10
93	Poor Sleep in Inflammatory Bowel Disease Is Reflective of Distinct Sleep Disorders. Digestive Diseases and Sciences, 2022, 67, 3096-3107.	1.1	10
94	The Host-Microbiome Response to Hyperbaric Oxygen Therapy in Ulcerative Colitis Patients. Cellular and Molecular Gastroenterology and Hepatology, 2022, 14, 35-53.	2.3	10
95	Development and Feasibility of a Web-Based Decision Aid for Patients With Ulcerative Colitis: Qualitative Pilot Study. Journal of Medical Internet Research, 2021, 23, e15946.	2.1	9
96	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Clinical Gastroenterology and Hepatology, 2022, 20, 2619-2627.e1.	2.4	9
97	An Office-Based, Point-of-Care Test Predicts Treatment Outcomes With Community-Based Pelvic Floor Physical Therapy in Patients With Chronic Constipation. Clinical Gastroenterology and Hepatology, 2023, 21, 1082-1090.	2.4	9
98	Improving quality of care in IBD: A STEEEP challenge. Inflammatory Bowel Diseases, 2010, 16, 134-136.	0.9	8
99	Placing Value on Telemedicine for Inflammatory Bowel Disease. American Journal of Gastroenterology, 2019, 114, 382-383.	0.2	8
100	OUP accepted manuscript. International Journal for Quality in Health Care, 2021, 33, ii40-ii47.	0.9	8
101	A Web-Based Decision Aid (myAID) to Enhance Quality of Life, Empowerment, Decision Making, and Disease Control for Patients With Ulcerative Colitis: Protocol for a Cluster Randomized Controlled Trial. JMIR Research Protocols, 2020, 9, e15994.	0.5	8
102	Patient-Specific Approach to Combination Versus Monotherapy with the Use of Antitumor Necrosis Factor Î± Agents for Inflammatory Bowel Disease. Gastroenterology Clinics of North America, 2012, 41, 411-428.	1.0	7
103	IBD LIVE Case Seriesâ€”Case 3. Inflammatory Bowel Diseases, 2015, 21, 2958-2968.	0.9	7
104	Are We Ready to Include Prognostic Factors in Inflammatory Bowel Disease Trials?. Current Pharmaceutical Design, 2019, 25, 64-68.	0.9	7
105	What Options Do We Have for Induction Therapy for Crohnâ€™s Disease?. Digestive Diseases, 2010, 28, 543-547.	0.8	6
106	Beware of the Swinging Pendulum: Anti-Tumor Necrosis Factor Monotherapy vs Combination Therapy for Inflammatory Bowel Disease. Gastroenterology, 2014, 146, 884-887.	0.6	5
107	Beyond disease activity to overall disease severity in inflammatory bowel disease. The Lancet Gastroenterology and Hepatology, 2017, 2, 624-626.	3.7	5
108	Integrated Care for Crohnâ€™s Disease: A Plea for the Development of Clinical Decision Support Systems. Journal of Crohn's and Colitis, 2018, 12, 1499-1504.	0.6	5

#	Article	IF	Citations
109	Hemophagocytic Lymphohistiocytosis Occurring in Inflammatory Bowel Disease: Systematic Review. Digestive Diseases and Sciences, 2021, 66, 843-854.	1.1	5
110	IBD LIVE Case Seriesâ€"Case 1. Inflammatory Bowel Diseases, 2014, 20, 1696-1701.	0.9	4
111	Evaluating Study Withdrawal Among Biologics and Immunomodulators in Treating Ulcerative Colitis. Inflammatory Bowel Diseases, 2016, 22, 933-939.	0.9	4
112	Mo1846 Delivering High Value IBD Care Through Telemedicine Visits. Gastroenterology, 2016, 150, S792.	0.6	4
113	Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit All. Clinical Gastroenterology and Hepatology, 2018, 16, 1829-1831.	2.4	4
114	Day Care Attendance and Infectious Complications in Children Born to Mothers With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	4
115	Development of Balanced Whole System Value Measures for Inflammatory Bowel Disease Care in the IBD Qorus Collaborative Using a Modified Delphi Process. Inflammatory Bowel Diseases, 2021, , .	0.9	4
116	Identifying and Predicting the Goals and Concerns Prioritised by Individuals with Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2022, 16, 379-388.	0.6	4
117	Symptoms of central sensitization in patients with inflammatory bowel diseases: a case-control study examining the role of musculoskeletal pain and psychological factors. Scandinavian Journal of Pain, 2021, 21, 283-295.	0.5	4
118	Is the Hype of Medical Marijuana All Smoke and Mirrors?. American Journal of Gastroenterology, 2016, 111, 161-162.	0.2	3
119	Deâ€escalating medical therapy in Crohnâ€™s disease patients who are in deep remission: A RAND appropriateness panel. GastroHep, 2019, 1, 108-117.	0.3	3
120	Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach. Current Drug Targets, 2018, 19, 740-747.	1.0	3
121	Performance Characteristics of a Clinical Decision Support Tool for Disease Complications in Crohnâ€™s Disease. Crohn's & Colitis 360, 2021, 3, .	0.5	3
122	Health Economic Impact of a Multicenter Quality-of-Care Initiative for Reducing Unplanned Healthcare Utilization Among Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2021, 116, 2459-2464.	0.2	3
123	Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND appropriateness panel. American Journal of Gastroenterology, 2022, Publish Ahead of Print, .	0.2	3
124	Hyperbaric Oxygen as Successful Monotherapy for a Severe Ulcerative Colitis Flare. Inflammatory Bowel Diseases, 2022, 28, 1474-1475.	0.9	3
125	Previous Cancer in a Patient with CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2015, 21, 1.	0.9	2
126	A qualitative inquiry into patientsâ€™ perspectives on individualized priorities for treatment outcomes in inflammatory bowel diseases. Quality of Life Research, 2020, 29, 2403-2414.	1.5	2

#	Article	IF	Citations
127	Health Confidence Is Associated With Disease Outcomes and Health Care Utilization in Inflammatory Bowel Disease: A Nationwide Cross-sectional Study. Inflammatory Bowel Diseases, 2021, , .	0.9	2
128	As if mothers donÊ¼t have enough to worry aboutâ€¦. Inflammatory Bowel Diseases, 2006, 12, 146-147.	0.9	1
129	Risks and Side Effects of Medical Therapy. , 2019, , 125-132.		1
130	Management of IBD Patients Who Are Unwilling or Unable to Receive Infusion Therapy During the COVID-19 Pandemic. Inflammatory Bowel Diseases, 2020, 26, e137-e137.	0.9	1
131	Risks of Development of COVID-19 Among Patients With Inflammatory Bowel Disease: A Comparative Assessment of Risk Factors for Incident Infection. Crohn's & Colitis 360, 2022, 4, .	0.5	1
132	Bidirectional Correlations Between Health Confidence and Inflammatory Bowel Disease Activity: A Nationwide Longitudinal Cohort Study. Inflammatory Bowel Diseases, 0, , .	0.9	1
133	Reply. Clinical Gastroenterology and Hepatology, 2016, 14, 914-915.	2.4	0
134	Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease. , 2018, , 101-112.		0
135	Identifying and Predicting the Goals and Concerns of Individuals with Inflammatory Bowel Disease. SSRN Electronic Journal, 0, , .	0.4	0
136	Patient decision tools in inflammatory bowel disease. Gastroenterology and Hepatology, 2013, 9, 585-7.	0.2	0
137	Management of Inflammatory Bowel Disease With Telemedicine. Gastroenterology and Hepatology, 2020, 16, 526-528.	0.2	0
138	Appropriateness of Medical and Surgical Treatments for Chronic Pouchitis Using RAND/UCLA Appropriateness Methodology. Digestive Diseases and Sciences, 2022, , 1.	1.1	0